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Characterization of Antibody-Antigen Interactions
by Fluorescence Spectroscopy
Sotiris Missailidis and Kevin Brady
1. Introduction
Fluorescence spectroscopy is a widely used technique for the characteriza-
tion of molecular interactions in biological systems. It is highly sensitive, and
allows measurements at low sample concentrations (down to 10–7 M). It is also
available at a reasonably low equipment cost. These features make fluores-
cence spectroscopy an attractive technique as compared to other forms of opti-
cal spectroscopy.
Fluorescence is a three-stage process that occurs in certain molecules known
as fluorophores or fluorescent dyes (generally polyaromatic hydrocarbons or
heterocycles). The process leading to fluorescence emission from such mole-
cules is illustrated by the Jablonski diagram (Fig. 1). The first stage is the exci-
tation step, in which the fluorophore absorbs a photon of energy hvEX and
becomes an excited electronic singlet state (S1′). The excitation wavelength is
usually the same as the absorption wavelength of the fluorophore. The second
stage is the excited-state lifetime, when the excited state exists for a finite
period of time (typically 1–10 × 10–9 s). During this period, the fluorophore
undergoes conformational changes and is also subject to possible interactions
with its molecular environment, with two important consequences. First, the
energy of S1′ is partially dissipated, yielding a relaxed singlet excited state (S1)
from which fluorescence emission originates. Second, not all the molecules
initially excited by absorption (stage 1) return to the ground state (S0) by fluo-
rescence emission, as other processes such as collisional quenching, fluores-
cence energy transfer, and intersystem crossing may also depopulate S1. The
third stage is fluorescence emission, when a photon of energy hvEM is emitted,
returning the fluorophore to its ground state S0. Because of energy dissipation
during the excited-state lifetime, the energy of this photon is lower, and thus of
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a longer wavelength, than the excitation photon hvEX. Consequently, the ratio
of the number of fluorescence photons emitted (stage 3) to the number of pho-
tons absorbed (stage 1) represents the fluorescence quantum yield.
The fluorescence process recurs, and the same fluorophore can be repeatedly
excited and detected. For polyatomic molecules in solution, the discrete elec-
tronic transitions represented by hvEX and hvEM in Fig. 1 are replaced by broad
energy spectra known as the fluorescence excitation and fluorescence emission
spectrum, respectively. With few exceptions, the excitation spectrum of a single
species in dilute solution is identical to its absorption spectrum. Under the
same conditions, the fluorescence emission spectrum is independent of the
excitation wavelength, because of the partial dissipation of excitation energy
during the excited-state lifetime. The emission intensity is proportional to the
amplitude of the fluorescence excitation spectrum at the excitation wavelength.
Fluorescence emission intensity depends on the same parameters as
absorbance—defined by the Beer-Lambert law as the product of the molar
extinction coefficient, optical pathlength, and concentration—as well as on the
fluorescence quantum yield, the intensity of the excitation source, and the effi-
ciency of the instrument and, in dilute solutions, is linearly proportional to
these parameters.
Fluorescence is an absorption/emission phenomenon that has been associ-
ated with a number of biological molecules and extensively reviewed in the lit-
erature (1). The induction of fluorescence is determined by the presence of
certain chromophores within a molecule. When examining proteins, these
chromophores are found in the aromatic amino acids tryptophan, tyrosine, and
phenylalanine, which have high densities of delocalized electrons. Of the three
aromatic amino acids, tryptophan has by far the greatest contribution to the flu-
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Fig. 1. The Jablonski diagram illustrates the three stages involved in the creation of
an excited electronic singlet state by optical absorption and subsequent emission of flu-
orescence.
orescence of proteins. Its excitation wavelength is approx 295 nm. The emis-
sion wavelength varies according to the local environment of the tryptophans—
e.g., 320 nm for buried residues, and 360 nm for solvent exposed residues.
Alterations in intensity of the tryptophan emission spectrum can be studied
when an antibody is involved in a binding event. A reduction in the intensity of
the fluorescence emission is observed upon binding of the antibody to its anti-
gen. However, such a reduction is dependent upon the presence of tryptophan
residues in the vicinity of the antibody binding-pocket that would make them
susceptible to the minor alterations in the antibody structure upon binding, thus
resulting in the reduction of their fluorescence emission. This is known as fluo-
rescence quenching, and is especially useful when the binding partner, the anti-
gen, contains no fluorescent chromophores and is thus invisible to the
fluorimeter. When studying the intensity of the antibody fluorescent signal, the
changes observed are solely caused by the change in the environment of the
tryptophans within the antibody.
Two methods are described here for the study of antibody-antigen interac-
tions using fluorescence quenching. The first method is based on keeping the
antibody concentration constant and varying the antigen concentration accord-
ingly to achieve various antibody-antigen ratios. This is an inverse titration, in
which the first point measured is that of the antibody-antigen complex, when
the antigen is in excess and maximum binding has been achieved. The antigen
concentration is reduced at subsequent steps as aliquots of the antibody-antigen
complex are replaced by aliquots of free antibody at the same concentration. A
final point of free antibody in the absence of antigen is measured.
The second method is based on continuously increasing antigen concentra-
tions throughout the titration. This method is a straightforward titration, in
which the first point is that of free antibody, to which aliquots from a stock anti-
gen solution are added until antigen is in excess in solution and saturation of all
antigen-binding pockets of the antibody has been achieved. The data must then
be normalized as the volume, and thus the concentration of the antibody
changes every time an antigen aliquot is added to the solution. This method
presents the significant advantage of using much smaller amounts of antibody
material. However, normalizing data for volume addition has the potential to
incorporate errors in a system that is so sensitive to volume changes. It is there-
fore imperative to know how sensitive your system is to changes in
volume/concentration before you use this method of analysis. Each of the two
methods therefore presents certain advantages and disadvantages (see Notes 1
and 2), which should be considered before an appropriate choice of method is
made. Furthermore, both methods have a general applicability and can be used
with other spectroscopic techniques for the analysis of molecular interactions,
including those of antibody-antigen interactions (see Note 3).
Fluorescence Spectroscopy 433
The analysis of the data is sometimes as important as taking the experi-
mental measurements. In the past, many workers have employed the
Scatchard analysis plots for determining equilibrium association constants ka.
Scatchard analysis was first introduced (2) to provide data from straight-line
plots produced for systems that were completely homogeneous and
monomeric. An examination of most of the published uses of Scatchard plots
makes it clear that many workers fit linear plots through nonlinear data. These
situations oversimplify the binding event, and can incorporate large errors in
the determination of binding constants. We therefore recommend (see Note 4)
that users analyze their data using Equation 1 (3,4) or variations of it using
nonlinear least squares fitting, which would alleviate such problems of data
fitting:
Equation 1: Quadratic equation for fitting binding curves.
where K is the equilibrium association constant, d is the concentration of
antibody, E1 is the maximum value of Acalc(P0), and E2 is the ratio Fo/F at F
equal to Fo (no antigen present) and therefore equals 1. Acalc(P0) is the calcu-
lated parameter representing Fo/F, the maximum fluorescence of the free anti-
body divided by the fluorescent signals obtained in the presence of quenching
antigen. P0 is the total antigen concentration. Values of Fo/F for each antigen
concentration vs antigen concentration at each titration point will have to be
imported. Values of K and E1 are iteratively manipulated until the best fit of
line to data is achieved or computer-calculated for best fit.
2. Materials
1. Phosphate-buffered saline (PBS): dissolve one PBS tablet (Sigma; cat. #P4417) in
200 mL of distilled water to give yield 0.01 M phosphate buffer, 0.0027 M KCl, and
0.137 M NaCl, pH 7.4; sterile-filter through a 0.22-µm filter.
2. Antibody of interest: store the antibody at –20°C in small aliquots to avoid denatu-
ration or inactivation from repeated freeze-thaw cycles.
3. Antigen of interest: Depending on the nature of your antigen—if it is a small pep-
tide, keep under dry conditions as solid and dissolve in buffer as needed, whereas if
it is a protein in solution, also keep frozen in small aliquots to avoid denaturation or
inactivation through repeated freeze-thaw cycles.
4. Measurements can be taken in any fluorimeter available in your laboratory, using
fluorescence quartz cuvet. We have used a Perkin-Elmer LS-5 luminescence
spectrometer.
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3. Methods
3.1. Using Fixed Antibody Concentration
When using a fixed concentration of the antibody and varying concentra-
tions of the antigen, one can produce a binding curve from which equilibrium
constants KA and KD can be derived. This method was previously employed by
Reedstrom et al. (5) for the study of protein-DNA interactions, but it can
equally be applied to the study of antibody-antigen interactions as well as most
intermolecular interactions. The method of using fixed antibody concentration
is in fact a reverse titration, in which the initial measurement is of antibody
fully saturated by antigen and the last is of free antibody.
1. Prepare in a fluorescence quartz cuvet a 2-mL solution of the antibody/antigen mix-
ture. The initial concentration of the antibody should be 0.26 µM, expressed in anti-
gen-binding pockets (or 0.13 µM of whole IgG molecules); the initial concentration
of antigen epitopes should be 1.5 µM. If a multimeric antigen is used, be sure to
calculate the concentration per epitope and not for the whole antigen. It is generally
believed that antibody-antigen interactions are straightforward, one-to-one interac-
tions. However, this is not always the case, and care should be taken in calculating
the concentration of antigen per epitope and of the antibody per antigen-binding
pocket. Cooperativity effects can be observed with multimeric antigens with many
epitopes, and this should be taken into consideration when calculating the associa-
tion constants (see Note 5). The excess concentration of antigen epitopes (~5.8:1)
ensures total saturation of all antigen-binding pockets on the antibody.
2. Prepare a separate free antibody solution, of 10 mL in volume and at the same con-
centration as that in the cuvet (0.26 µM expressed in antigen-binding pockets).
3. Adjust the fluorimeter settings to: excitation slit width at 5 nm; emission slit width
at 10 nm; excitation wavelength at 290 nm; and emission wavelength at 345 nm.
4. Measure the fluorescence emission of the solution (F; observed intensity of fluores-
cence in the presence of varying amounts of antigen).
5. Remove from the cuvet 750 µL of antibody/antigen complex solution and replace it
with 750 µL of the free antibody solution. Allow the mixture to equilibrate for 1
min and measure the fluorescence emission.
6. Repeat step 5 for ten consecutive times and record the data. During steps 5 and 6
the antigen concentration is reduced exponentially over the ten replacements of the
antibody-antigen mixture with free antibody, while keeping the antibody concen-
tration unchanged throughout the titration (Fig. 2).
7. Clean the cuvet and fill it with the remainder of the pure antibody solution. Take the
measurement of the emission. This value will give you the fluorescence emission of
free antibody in solution (Fo). Fit the data using Equation 1 (3,4) or variations of it
using nonlinear least squares fitting. You can use this equation in any data-plotting
program available in your laboratory. We have used this equation in two different
programs, MathCad and Origin. If you are using MathCad for fitting your data,
then you should perform iterative, manual manipulations to achieve best fit. If you
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are using Origin, the program will automatically calculate the values for E1 and K
to achieve best fit.
3.2. Using Increasing Amounts of Antigen
A direct titration, in which increasing amounts of antigen are added to an
antibody solution and the change in fluorescence is measured at each addition
point, can also be employed for the identification of equilibrium binding con-
stants. This method is based on the work of Parker (6), in which small aliquots
of antigen are added to a solution of antibody, and the signal is monitored. The
signal is normalized for the dilution effect of adding the antigen to the antibody
solution. ka is then determined by plotting the data. This is a direct titration, in
which the first point is that of free antibody and the last point is with the anti-
body fully saturated by antigen.
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Fig. 2. Relationship between the number of total antigen epitopes and total antigen-
binding sites over the course of a flourescence quenching experiment (method one).
The antibody concentration remains constant throughout, and the antigen concentration
decreases exponentially. Initially there is an excess of antigen epitopes (ratio of 5.8:1,
antigen:antibody). At about replacement number 4, there is almost a 1:1 ratio of antigen
to antibody. Finally, the antigen concentration decreases to an extent in which there is a
large excess of antibody binding sites (ratio of 1:19.6, antigen:antibody). In this way,
the occupancy of binding pockets by antigen changes from fully saturated at the start to
about 5% occupancy at the end of the experiment.
1. Prepare 2.5 mL of an antibody solution at a concentration of 0.12 µM in PBS, pH
7.4 (0.018 mg/mL for an IgG antibody). This equals an antigen-binding pocket
concentration of 0.24 µM.
2. Place 2.0 mL of the antibody solution in a 3-mL fluorescence quartz~ cuvet of 1-
cm cell path length.
3. Adjust the fluorimeter settings to: excitation slit width at 5 nm; emission slit width
at 10 nm; excitation wavelength at 290 nm; and emission wavelength at 345 nm.
4. Measure the fluorescence emission of the free antibody solution (Fo; observed
intensity of antibody fluorescence in the absence of its antigen).
5. Prepare an antigen solution in PBS at a concentration of 60 µM. The large differ-
ence in concentration between the antigen and antibody lessens the need for adding
large volumes to the antibody solution in step 6, thus minimizing the dilution effect
on fluorescence emission.
6. Add 1-µL aliquots of the antigen solution to the cuvet. Mix well and measure the
fluorescence emission (F: observed fluorescence in the presence of varying
amounts of antigen). Each addition of an antigen aliquot will add a concentration of
0.03 µM of antigen to the antibody solution.
7. It will take you eight additions (experimental points) before you almost reach the
one-to-one ratio (antigen epitope to antigen-binding pocket). Make sure you con-
tinue your titration to an excess of antigen to antibody, until you achieve several
points where the fluorescence does not change (or decreases very slightly because
of dilution effects) from measurement to measurement. If your antigen is not as sol-
uble and you have difficulties achieving such concentrations, prepare your antigen
in as concentrated a form as possible, making sure to adjust the volumes of the anti-
gen aliquots added to the antibody solution for each measurement.
8. Record the fluorescence emission (F; observed intensity of fluorescence in the pres-
ence of varying amounts of antigen) at each step of your titration.
9. Correct for dilution effects resulting from the addition of antigen to your antibody
solution. Dilution effects of titrating antigen solution into the antibody solution
should be determined by titrating PBS into 2 mL of antibody solution as a control.
10. Plot your data Fo/F vs the antigen concentration, using Equation 1 (see Subhead-
ing 1.) or any of the available equations for the fitting of binding data, based on
nonlinear squares fitting, that would result in the calculation of the association
equilibrium constant that represents the binding affinity of your antibody for the
given antigen (see Subheading 3.1., step 7). For fitting data resulting from this
method, be sure to consider the dilution in antigen concentration caused by the
change in votal volume after each addition of antibody solution.
4. Notes
1. Method one, in which fixed antibody colcentration is used throughout the titration,
has an obvious advantage—the concentration of the antibody does not change, thus
resulting in more accurate data and equilibrium-constant determination. Therefore,
method one should be used, especially if the system is susceptible to changes
depending on concentration, or is concentration/volume sensitive in any way.
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2. Method two presents an advantage over method one because much smaller
amounts of antibody are utilized. If sample volume is of the essence, then method
two is obviously preferred. However, if at all possible, you would be advised to
compare at least once the two methods in your system to determine if and how
much concentration/volume changes are affecting your measurements.
3. Both methods described here could be used for any other titrations using optical
spectroscopy, such as ultraviolet (UV) or Circular Dichroism (CD) spectroscopy.
The only alteration is that these techniques require higher concentrations, and you
should adjust your concentrations accordingly to get the required signal. A 10-fold
higher antibody concentration (approx 2.3 × 10–6 M or 0.35 mg/mL for an IgG anti-
body) is usually required to obtain a sufficient signal in the UV and CD spec-
trophotometer in order to perform a titration and obtain equilibrium binding
constants. Furthermore, it should be noted here that if you have access to CD spec-
trophotometer, you can also obtain structural information about your antibody, or
changes that occur upon antigen binding, by analyzing the CD spectra in any of the
software programs available for CD data analysis.
4. Avoid using Scatchard analysis for fitting your data. It is an outdated and oversim-
plified representation of the binding event, and can incorporate significant errors in
the calculations of the equilibrium binding constants.
5. It is generally accepted that antibody-antigen interactions are classic cases of one-
to-one interactions without any cooperativity effects. The antigen-binding site is
believed to accommodate a single hapten molecule, and studies also indicate that
binding sites in immunoglobulins do not interact in binding of haptens in solution.
However, this is not necessarily the case, and avidity can play a part in some exper-
iments in which polymeric antigens with more than one epitope bind to the same
antibody’s binding sites. This should be taken into account when analyzing the data
obtained from such experiments. When one epitope is available per antigen, the
association constant reflects that of the single interaction between one epitope and
one binding site, with no avidity effects occurring and comparable to association
constants described in the literature for antibodies interacting with single epitope
molecules. Such an interaction is illustrated in Fig. 3. Polymeric antigens with
many epitopes may allow two epitopes on the same molecule to interact simultane-
ously with the same antibody. The possibility of avidity effects on the binding inter-
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Fig. 3. Monovalent binding of antibody to antigen.
actions thus exists. It is important to utilize an accurate binding model that would
account for such an interaction (Fig. 4). The binding models for mono- and multi-
valent binding interactions are shown in Equation 2. For monovalent interactions,
ka, the equilibrium association constant can be described as:
(2)
Multivalent interactions require a more complex model. The following exam-
ple shows the interaction between an antibody Ab(2) with two binding pockets and
an antigen Ag(3) with three epitopes. (AbAg) represents a binding pocket/epitope
complex. Numbers in subscript indicate unbound binding pockets/epitopes.
Or
Rearrange to substitute out the Ab(1) (AbAg)Ag(2) term to give
K
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Fig. 4. Monovalent and multivalent binding of polymeric antigens with multiple epitopes.
(3)
Then
(4)
Substitution into Equation 4 also gives:
(5)
There are two equilibrium association constants kA1 and kA2 depending on
the concentration of antigen in the mixture. In antigen excess, there is monova-
lent binding with each antibody that associates with one epitope on two sepa-
rate antigen molecules. This gives the association constant which represents the
true affinity of the interaction, kA1. In antibody excess, there is bivalent binding
of one antibody molecule to two epitopes on the same antigen molecule. This
yields the association constant, which incorporates in part the true affinity, as
well as avidity, kA2. So when analyzing the data obtained, it is important to do
two fittings. For points measured at antigen excess, the graph is produced using
the monovalent binding model. For points at antibody excess, the graph is fitted
using the bivalent model. kA2 is greater than kA1 and the association rate is
higher for kA2. This is because the second epitope has lost entropy as a result of
the complex formed on the same antigen molecule by the first epitope. In
effect, the binding of one epitope restricts the conformational space the rest of
the antigen molecule can explore before finding a free antigen-binding pocket.
The likelihood of associating with the remaining free antigen-binding pocket
on the same antibody molecule is much higher because of closer proximity.
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